Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — FY2016 Earnings Presentation
13 slides from Matinas Biopharma's earnings presentation, Apr 3, 2017
Slide 1: Quarterly Update Conference Call and Webcast
www.matinasbiopharma.com NYSE MKT: MTNB Quarterly Update Conference Call and Webcast April 3, 2017
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other st
Slide 3: Jerome D. Jabbour, President
Jerome D. Jabbour President 3
Slide 4: Recent Highlights Set the Stage for a Transformational 2017
Recent Highlights Set the stage for a transformational 2017 Anti - Infective Development Program Achievements - Launched Phase 2 development program for lead anti - infective candidate, MAT2203, an orally - administered, encochleated formulation of the broad spectrum fungicidal medication amphoteric
Slide 5: FY2016 Financial Overview
FY2016 Financial Overview 5 Cash following warrant tender - Jan. 19, 2017 $16.8M Cash to fund programs through multiple key data points - Q2 2018 Cash as of Dec. 31, 2016 $4.1M
Slide 6: Roelof Rongen, Chief Executive Officer
Roelof Rongen Chief Executive Officer 6
Slide 7: MAT2501 Targeting NTM and Drug-Resistant Gram-Negative Bacterial Infections
MAT2501 Targeting NTM and Drug - Resistant Gram - Negative Bacterial Infections • MAT2501 formulates the broad - spectrum aminoglycoside Amikacin into our lipid - crystal nano - particle cochleate technology • Active IND for the treatment of Non - Tuberculous - Mycobacterium (NTM) infections (enviro
Slide 8: MAT2501 Positive Phase 1 Results
MAT2501 Positive Phase 1 Results • Single - ascending - dose study in healthy volunteers (200, 400, 800mg) • Evaluated drug kinetics (blood, urine, feces), tolerability and acute safety • Peak blood levels were an area of focus; IV amikacin is know to generate high peak levels with potential kidney
Slide 9: MAT2501 Has High Differentiation Potential in Anti-Infective Arena
9 MAT2501 has High Differentiation Potential in a Rapidly Evolving Anti - Infective Arena Preclinical screening work in drug - resistant gram negative infections: e.g. UTI, pneumonia, Acinetobacter, E. coli, Kliebsiella NTM Infections: • Lung, refractory to guideline therapy • M. abscessus • Cystic
Slide 10: MAT2203: C-Amphotericin B
MAT2203: C - Amphotericin B • Broad Spectrum Fungicidal - Amphotericin B is perhaps the broadest spectrum antifungal agent - Designated as QIDP with Fast Track Status for treatment of aspergillus, invasive candidiasis and prevention of invasive fungal infection • Few Drug – Drug Interactions - Does
Slide 11: MAT2203: Phase 2 Program to Support Phase 3 Development for IFI Prevention
MAT2203: Phase 2 Program to Support Phase 3 Development for IFI Prevention Mucocutaneous Candidiasis, up to N=16 Phase 2 Studies Vulvovaginal Candidiasis N=75 Tolerability PK & Other N=16 - 20 Efficacy versus active control in larger patient population Tolerability/other clinical factors in immunoco
Slide 12: Q&A
Q&A MATINAS
Slide 13: Quarterly Update Conference Call and Webcast
www.matinasbiopharma.com NYSE MKT: MTNB Quarterly Update Conference Call and Webcast April 3, 2017
Matinas BioPharma Holdings — FY2016 Earnings Presentation on 6ix